Sodium Starch Glycolate - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The sodium starch glycolate market size is expected to grow from USD 86.70 million in 2025 to USD 91.70 million in 2026 and is forecast to reach USD 125.30 million by 2031 at 6.44% CAGR over 2026-2031. This report is Segmented by Source (Potato Starch Based, Corn Starch Based, Wheat Starch Based, Other Starch Sources), Application (Pharmaceuticals, Food Processing, Personal Care and Cosmetics, and Other Applications), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD Million).

Global Sodium Starch Glycolate Market Trends and Insights

Rising global generic drug production

The sodium starch glycolate market continues to benefit directly from rising generic pharmaceutical output across regulated and emerging markets. The United States Food and Drug Administration approved 76 first-generic drugs in 2024, and that flow of approvals keeps creating new formulation demand for compendial excipients used in tablet manufacturing. A key advantage for sodium starch glycolate market suppliers is that broad pharmacopeial alignment reduces documentation friction for companies that want to serve both the United States and European product pipelines. Prequalification pathways also widen the addressable demand base because manufacturers that qualify products for public health procurement need excipients that fit recognized quality frameworks. As more multisource products enter large tablet categories, manufacturers that already standardize on sodium starch glycolate tend to keep it in place because requalification work on core excipients adds time and cost.

Growing nutraceutical tablet and capsule demand

The sodium starch glycolate market is gaining added support from the steady expansion of nutraceutical tablets and capsules. This format mix matters because tablets remain attractive for producers that want precise dosing, scalable output, and stable shelf life across a wide product range. Sodium starch glycolate fits this setting well because its low use level helps formulators manage cost while still supporting fast breakup in compressed products. Suppliers and customers are also narrowing the gap between supplement-grade and drug-grade specifications as retailers and brand owners place more attention on consistency, documentation, and quality claims. The result is a broader demand pool for the sodium starch glycolate market that is no longer tied only to prescription and generic drug production.

Raw material price volatility in starch feedstocks

The sodium starch glycolate market faces a clear restraint from raw material volatility because starch feedstocks remain exposed to agricultural cycles, fertilizer costs, and energy pass-through. Roquette's March 2026 market update for Europe noted pressure across the cereal complex and linked the environment to weather uncertainty and wider energy and fertilizer stress. This matters more in potato-based grades because the feedstock base is concentrated in Northern Europe, which makes procurement more sensitive to regional crop conditions and cost swings. Producers that supply pharmaceutical customers under fixed or slower-moving contracts cannot always pass higher input costs through immediately, so margin pressure builds quickly. The sodium starch glycolate market also shows a split between commodity grades and higher-value pharmaceutical grades, which means not every supplier has the same pricing power when raw materials move against them.

Other drivers and restraints analyzed in the detailed report include:

• Clean label and plant-based excipient preference
• Innovation in Novel Drug Delivery Systems (NDDS)
• Regulatory burden across pharmacopeial grades

Segment Analysis

Potato Starch-based SSG held 38.7% of the sodium starch glycolate market share in 2025, and that led to formulation preference more than simple feedstock availability. Potato-derived grades are associated with phosphorous cross-link chemistry, and that profile supports chemical stability that is especially valued in moisture-sensitive formulations. The source has also benefited from long-standing pharmacopeial familiarity, which helps manufacturers working across regulated tablet programs. European producers and users have stayed loyal to this source because regional supply access, Drug Master File support, and a long qualification history reduce the need to revisit core excipient choices.

Corn Starch-based SSG is projected to deliver the fastest sodium starch glycolate market size growth at a 6.32% CAGR from 2026 to 2031. Its growth case is tied to broader agricultural availability across North America and East Asia, which gives suppliers a more diversified feedstock base than the more regionally concentrated potato chain. That broader base supports sourcing resilience for the sodium starch glycolate industry, especially in markets that want lower import dependence and more predictable year-round availability.

Complete Report Scope:

• By Source
  • Potato Starch Based
  • Corn Starch Based
  • Wheat Starch Based
  • Other Starch Sources
• By Application
  • Pharmaceuticals
  • Food Processing
  • Personal Care and Cosmetics
  • Other Applications
• By Geography
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Geography Analysis

Asia-Pacific accounted for 34.8% of the sodium starch glycolate market share in 2025, making it the largest regional base for current demand. India and China anchor this position because their tablet and capsule manufacturing scale feeds directly into high-volume excipient procurement for generic medicines. Export-oriented Indian manufacturers increasingly need harmonized grades with strong documentation support, while a part of the Chinese domestic base still works with more price-led commodity supply. China's excipient Good Manufacturing Practice (GMP) annex, effective from January 1, 2026, is raising the local compliance floor and narrowing gaps with international expectations. Supplier investment in regional technical support is reinforcing the sodium starch glycolate market in Asia-Pacific, and DFE Pharma's Hyderabad center reflects the push to shorten formulation development cycles close to customer demand.

North America is expected to record the fastest sodium starch glycolate market size growth at a 5.8% CAGR through 2031. The regional outlook is supported by a strong pipeline of generic drug launches and by a nutraceutical sector that continues to favor tablet and capsule delivery formats. Demand is also benefiting from formulation upgrades and wider attention to natural-origin excipient options across regulated and adjacent health products. Ashland's 2026 tablet coatings investment in India still matters to North American strategy because it reflects a broader supply chain model built around dual sourcing and closer links with Asia-Pacific manufacturing nodes.

Europe remains an important but more mature part of the sodium starch glycolate market. The region houses advanced excipient producers such as DFE Pharma and Roquette, and their operations continue to influence quality expectations across global pharmacopeial supply. Roquette's portfolio expansion through the International Flavors and Fragrances Pharma Solutions deal widened its presence across oral dosage excipients and strengthened Europe's role in higher-value formulation support. South America and the Middle East and Africa remain smaller in size, but local pharmaceutical manufacturing and formulation capability investments are still creating incremental demand for the sodium starch glycolate market in those regions.

List of Companies Covered in this Report:

• DFE Pharma
• Roquette Frères
• JRS Pharma
• Colorcon
• Ashland
• BASF SE
• Merck KGaA
• Shin-Etsu Chemical Co., Ltd.
• Toshiba Chemical Corporation
• Avantor, Inc.
• Beneo GmbH
• Meggle Pharma
• Lubrizol Corporation
• Nihon Shokuhin Kako Co., Ltd.
• Anhui Sunhere Pharmaceutical Excipients Co., Ltd.
• Shreeji Pharma International
• Liaocheng A Hua Pharmaceutical Co., Ltd.
• Prachin Chemical
• Muby Chemicals
• Huzhou Zhanwang Pharmaceutical Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support